Acute Myocarditis in Children: An Overview of Treatment and Recent Patents.

IF 4.2 Q3 Pharmacology, Toxicology and Pharmaceutics
Ronald C M Fung, Kam L Hon, Alexander K C Leung
{"title":"Acute Myocarditis in Children: An Overview of Treatment and Recent Patents.","authors":"Ronald C M Fung,&nbsp;Kam L Hon,&nbsp;Alexander K C Leung","doi":"10.2174/1872213X14666200204103714","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pediatric myocarditis is rare but challenging. This overview summarized the current knowledge and recent patents on childhood myocarditis.</p><p><strong>Methods: </strong>Clinical queries and keywords of \"myocarditis\" and \"childhood\" were used as search engine.</p><p><strong>Results: </strong>Viral infections are the most common causes of acute myocarditis. Affected children often have a prodrome of fever, malaise, and myalgia. Clinical manifestations of acute myocarditis in children can be nonspecific. Some children may present with easy fatigability, poor appetite, vomiting, abdominal pain, exercise intolerance, respiratory distress/tachypnea, dyspnea at rest, orthopnea, chronic cough with wheezing, chest pain, unexplained tachycardia, hypotension, syncope, and hepatomegaly. Supraventricular arrhythmias, ventricular arrhythmias, and heart block may be present. A subset of patients have fulminant myocarditis and present with cardiovascular collapse, which may progress to severe cardiogenic shock, and even death. A high index of suspicion is crucial to its diagnosis and timely management. Cardiac magnetic resonance imaging is important in aiding clinical diagnosis while, endomyocardial biopsy remains the gold standard. The treatment consists of supportive therapy, ranging from supplemental oxygen and fluid restriction to mechanical circulatory support. Angiotensinconverting enzyme inhibitors, angio-tensin II receptor blockers, β-blockers, and aldosterone antagonists might be used for the treatment of heart failure while, immunosuppression treatments remain controversial. There are a few recent patents targeting prevention or treatment of viral myocarditis, including an immunogenic composition comprising a PCV-2 antigen, glutathione-S-transferase P1, neuregulins, NF-[kappa] B inhibitor, a pharmaceutical composition which contains 2-amino-2- (2- (4-octyl phenyl) - ethyl) propane 1,3-diol, a composition containing pycnojenol, Chinese herbal concoctions, and a Korean oral rapamycin. Evidence of their efficacy is still lacking.</p><p><strong>Conclusion: </strong>This article reviews the current literature regarding etiology, clinical manifestations, diagnosis, and management of acute myocarditis in children.</p>","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on inflammation & allergy drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1872213X14666200204103714","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 3

Abstract

Background: Pediatric myocarditis is rare but challenging. This overview summarized the current knowledge and recent patents on childhood myocarditis.

Methods: Clinical queries and keywords of "myocarditis" and "childhood" were used as search engine.

Results: Viral infections are the most common causes of acute myocarditis. Affected children often have a prodrome of fever, malaise, and myalgia. Clinical manifestations of acute myocarditis in children can be nonspecific. Some children may present with easy fatigability, poor appetite, vomiting, abdominal pain, exercise intolerance, respiratory distress/tachypnea, dyspnea at rest, orthopnea, chronic cough with wheezing, chest pain, unexplained tachycardia, hypotension, syncope, and hepatomegaly. Supraventricular arrhythmias, ventricular arrhythmias, and heart block may be present. A subset of patients have fulminant myocarditis and present with cardiovascular collapse, which may progress to severe cardiogenic shock, and even death. A high index of suspicion is crucial to its diagnosis and timely management. Cardiac magnetic resonance imaging is important in aiding clinical diagnosis while, endomyocardial biopsy remains the gold standard. The treatment consists of supportive therapy, ranging from supplemental oxygen and fluid restriction to mechanical circulatory support. Angiotensinconverting enzyme inhibitors, angio-tensin II receptor blockers, β-blockers, and aldosterone antagonists might be used for the treatment of heart failure while, immunosuppression treatments remain controversial. There are a few recent patents targeting prevention or treatment of viral myocarditis, including an immunogenic composition comprising a PCV-2 antigen, glutathione-S-transferase P1, neuregulins, NF-[kappa] B inhibitor, a pharmaceutical composition which contains 2-amino-2- (2- (4-octyl phenyl) - ethyl) propane 1,3-diol, a composition containing pycnojenol, Chinese herbal concoctions, and a Korean oral rapamycin. Evidence of their efficacy is still lacking.

Conclusion: This article reviews the current literature regarding etiology, clinical manifestations, diagnosis, and management of acute myocarditis in children.

儿童急性心肌炎:治疗综述及近期专利。
背景:小儿心肌炎是一种罕见但具有挑战性的疾病。本文综述了目前关于儿童心肌炎的知识和最新专利。方法:以“心肌炎”、“儿童期”的临床查询及关键词为搜索引擎。结果:病毒性感染是急性心肌炎最常见的病因。患病儿童通常有发热、不适和肌痛的前驱症状。儿童急性心肌炎的临床表现可以是非特异性的。部分患儿可表现为易疲劳、食欲不振、呕吐、腹痛、运动不耐受、呼吸窘迫/呼吸急促、休息时呼吸困难、矫形呼吸、慢性咳嗽伴喘息、胸痛、不明原因的心动过速、低血压、晕厥和肝肿大。可能出现室上性心律失常、室性心律失常和心脏传导阻滞。一部分患者有暴发性心肌炎并表现为心血管衰竭,这可能发展为严重的心源性休克,甚至死亡。高怀疑指数对其诊断和及时治疗至关重要。心脏磁共振成像在辅助临床诊断中很重要,而心内膜活检仍然是金标准。治疗包括支持治疗,从补充氧气和液体限制到机械循环支持。血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂、β阻滞剂和醛固酮拮抗剂可用于治疗心力衰竭,而免疫抑制治疗仍有争议。最近有一些针对预防或治疗病毒性心肌炎的专利,包括一种含有PCV-2抗原、谷胱甘肽- s -转移酶P1、神经调节蛋白、NF-[kappa] B抑制剂的免疫原性组合物,一种含有2-氨基-2-(2-(4-辛基苯基)-乙基)丙烷1,3-二醇的药物组合物,一种含有吡诺酚的组合物,中草药混合物,以及一种韩国口服雷帕霉素。目前仍缺乏其有效性的证据。结论:本文综述了儿童急性心肌炎的病因、临床表现、诊断和治疗方面的文献。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.90
自引率
0.00%
发文量
0
期刊介绍: Recent Patents on Inflammation & Allergy Drug Discovery publishes review articles by experts on recent patents in the field of inflammation and allergy drug discovery e.g. on novel bioactive compounds, analogs and targets. A selection of important and recent patents in the field is also included in the journal. The journal is essential reading for all researchers involved in inflammation and allergy drug design and discovery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信